GAITHERSBURG, Md., March 9, 2017 /PRNewswire/ -- MagBio Genomics, based in Gaithersburg, Maryland USA announces the launch of its new cfKapture 21 kit.
cfKapture 21 system is a circulating cell-free DNA (ccfDNA) isolation kit which includes a proprietary reagent that prevents post-separation degradation of plasma and ccfDNA fragments for up to 21 days at room temperature. This feature allows laboratories to safely transport and process samples within a much longer time frame without the need for extensive cold chain, which in turn reduces cost, improves efficiency, and increases outreach for both local and international samples. cfKapture 21 is the only kit on the market able to provide this level of flexibility for processing plasma samples in a high throughput setting.
cfKapture 21 kit is compatible with any whole blood collection tube. However it is best used in combination with the MagBio Blood STASIS 21-ccfDNA tube to ensure recovery of the highest quality ccfDNA suitable for most liquid biopsy applications. Blood STASIS 21-ccfDNA is a direct draw whole blood collection system with a proprietary blood stabilization reagent, compatible with almost all liquid biopsy applications for cancer genomic research and Non-invasive Prenatal testing (NIPT). Other blood collection and stabilization systems contain potential formaldehyde-releasing compounds which makes them unsuitable for many liquid biopsy applications.
In combination with MagBio's Blood STASIS 21- ccfDNA tube, the cfKapture 21 kit offers a highly efficient and cost effective solution to blood sampling handling and ccfDNA isolation.
"Currently, samples of plasma for the purposes of circulating cell-free DNA analysis (ccfDNA) need to be processed immediately. However, to maintain the integrity of ccfDNA within the samples they have to be shipped frozen with dry ice for the duration of the transport cycle. Shipping on dry ice is not only expensive, but there is also a high risk of compromising ccfDNA integrity, especially for samples shipped overseas with long transit times. Because stabilizing plasma samples during transport remains a major hurdle in obtaining meaningful data from ccfDNA, MagBio developed the cfKapture 21 purification kit to overcome this challenge.
The MagBio cfKapture 21 kit includes a reagent that allows short-term transport and storage of separated plasma at room temperature for 21 days while maintaining the stability of ccfDNA. With this unique feature, cfKapture21 now provides cancer research laboratories and NIPT centers flexibility in plasma sample processing as well as significant cost savings associated with sample handling in both manual and automated ccfDNA isolation settings"
Hyacinth Ntchobo, Ph.D. – CEO of MagBio Genomics, Inc.
cfKapture 21 kit is for Research Use Only (RUO)
About MAGBIO GENOMICS, INC.
MagBio Genomics, Inc. is an emerging biotechnology company based in Gaithersburg Maryland, USA that develops and commercializes magnetic bead-based products for nucleic acids isolation including biomarkers as tools for liquid biopsy.
Our current focus encompasses products that allow both safeguarding integrity of bio-samples and efficient isolation of circulating biomarkers from biological samples for human genetic research including cancer studies and non-invasive prenatal testing (NIPT).
Our core platform allows efficiency in the nucleic acids sequencing methods including Sanger and Next Generation Sequencing (NGS) in both manual and automated work flow. MagBio Genomics, Inc. serve customers including academic and private genomics research institutions, as well as clinical genomic research across the globe.
More information can be found http://www.magbiogenomics.com.
This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/magbio-genomics-launches-a-novel-solution-for-isolation-of-circulating-cell-free-dna-ccfdna-from-stabilized-plasma-sample-300421652.html
SOURCE MagBio Genomics, Inc.